SS-31 (Elamipretide / Forzinity)
TL;DR
- FDA-approved indication is Barth syndrome only — an ultra-rare X-linked genetic disorder (~1:300,000–1,000,000 males), granted via accelerated approval after the randomized portion of the pivotal trial failed its primary endpoints
- Phase 3 MMPOWER-3 (PMID 37268435) FAILED co-primary endpoints in general primary mitochondrial myopathy — no significant benefit in 6MWT or fatigue scores
- Phase 2 heart failure trials (SPIHF-203, PROGRESS-HF) were negative — no improvement in cardiac function at 4 weeks
- Single healthy older adult study (PMID 34264994): transient ATPmax improvement in one hand muscle, zero functional benefit
- Injection site reactions occur in 100% of users — erythema, pain, induration, pruritus
- Off-label use for mitochondrial health, performance, or anti-aging is not supported by the evidence — mechanism is condition-specific (cardiolipin abnormality), which is present in Barth syndrome but not in healthy adults
Why It Matters for Vitals
SS-31 is one of the most aggressively marketed mitochondrial compounds in the longevity space, frequently cited in biohacker communities as a “mitochondrial enhancer” for healthy adults. The reality is that the evidence base is narrowly confined to patients with confirmed genetic mitochondrial disorders. For healthy adults, athletes, or people using it as a general longevity intervention, the clinical evidence does not support any benefit.
| Factor | Relevance to SS-31 |
|---|---|
| No wearable signal | Zero published studies using consumer wearables to measure HRV, RHR, sleep, or activity during SS-31 treatment |
| Off-label use | All efficacy data comes from disease populations; no data in metabolically healthy adults |
| Injection burden | 100% injection site reaction rate; daily SC injection for a compound with no proven benefit in non-diseased populations |
| Cost | Orphan drug pricing; no insurance coverage for off-label use |
| Stack context | No established synergy with Retatrutide, GHK-Cu, BPC-157, or TB-500 |
Key Facts
| Parameter | Value |
|---|---|
| Chemical structure | Tetrapeptide: arginyl-2’,6’-dimethyltyrosyl-lysyl-phenylalaninamide |
| Molecular target | Cardiolipin (inner mitochondrial membrane) |
| Approved indication | Barth syndrome (FDA accelerated approval 2023) |
| Approved dose | 40 mg SC once daily |
| Route | Subcutaneous injection only |
| Bioavailability | ~92% absolute SC bioavailability |
| Half-life | ~2–4 hours; 100% recovered in urine by 48 hours |
| Notable excipients | Benzyl alcohol — not approved for neonates |
| Renal dose adjustment | Reduce to 20 mg/day if CrCl <30 mL/min |
| Elderly data | None — no subjects ≥65 enrolled in clinical trials |
Mechanism Summary
Cardiolipin binding
SS-31 binds cardiolipin, an anionic phospholipid exclusive to the inner mitochondrial membrane (IMM). Cardiolipin serves two critical roles:
- Structural — supports cristae architecture and organizes the electron transport chain (ETC) into supercomplexes for efficient oxidative phosphorylation
- Functional — modulates cytochrome c, determining whether it acts as an electron carrier (beneficial) or a peroxidase (harmful)
In pathological states, cardiolipin becomes peroxidized and depleted. SS-31 binding to cardiolipin:
- Prevents cytochrome c from converting to a peroxidase (inhibiting peroxidase activity that damages cardiolipin)
- Stabilizes cristae structure
- Promotes optimal oxidative phosphorylation
- Improves ADP sensitivity in aged mitochondria via the adenine nucleotide translocator (ANT)
- Activates the mitochondrial GSH/mitochondrial GPX4 (mitoGSH/mitoGPX4) pathway, alleviating mitochondrial ferroptosis (PMID 39364755, 2024)
Why it works in Barth syndrome but possibly not elsewhere
Barth syndrome is caused by loss-of-function mutations in TAFAZZIN, which directly disrupts cardiolipin remodeling. In this specific condition, cardiolipin itself is abnormal — SS-31’s cardiolipin-binding mechanism addresses the root pathology. In healthy adults or patients with age-related mitochondrial changes, there is no known cardiolipin abnormality to correct. The mechanism is condition-specific, which likely explains why benefits appear limited to genetically defined mitochondrial disorders.
Evidence Summary
✅ FDA-Approved Indication
Barth syndrome (TAFAZZIN mutations)
- TAZPOWER trial (NCT03098797): Phase 2/3 crossover, n=12 males ≥12 years
- Randomized portion failed to meet either primary endpoint (6MWT, BTHS-SA fatigue scores)
- Benefits observed only at 36 weeks in open-label extension (unblinded, no control group)
- OLE data at 168 weeks: +96.1 m 6MWT (p=0.003 vs baseline), improved cardiac volumes, MLCL/CL ratio improvement
- This is the evidence base for FDA accelerated approval — granted on unblinded open-label data in 12 patients
❌ General Primary Mitochondrial Myopathy — Failed Phase 3
MMPOWER-3 (PMID 37268435, Neurology 2023)
- Phase 3 RCT, n=218 adults with genotypically diverse primary mitochondrial myopathy
- 40 mg SC daily × 24 weeks
- FAILED co-primary endpoints: 6MWT difference −3.2 m (95% CI −18.7 to 12.3, p=0.69); PMMSA fatigue difference −0.07 (95% CI −0.10 to 0.26, p=0.37)
- Post-hoc: 74% with mtDNA pathogenic variants showed NO difference; only POLG/TWNK nDNA variant subgroup showed benefit (post-hoc, requires confirmatory trial)
❌ Heart Failure — Negative Phase 2
| Trial | Population | Result |
|---|---|---|
| SPIHF-203 (NCT02814097) | HFpEF, n=46, 40mg × 28 days | No effect on E/e’; null for 6MWT, NT-proBNP, LV strain |
| PROGRESS-HF (PMID 32068002) | HFrEF, n=71, 40mg × 4 weeks | No improvement in LVESV vs placebo |
❌ Healthy Older Adults — No Functional Benefit
PMID 34264994
- Single dose in 39 healthy older adults (60–85 years)
- Improved mitochondrial ATPmax in FDI hand muscle
- No significant effect on fatigue resistance; transient (disappeared by day 7); limited to one muscle; zero functional improvement
⚠️ Other Indications — Data Insufficient
| Indication | Status |
|---|---|
| Dry AMD (NCT05162768) | Phase 2/3 completed; no peer-reviewed results published |
| LHON eye drops (NCT02693119) | Phase 2 completed; primary endpoints were safety only |
Safety Profile
Injection site reactions — 100% expected
| Reaction | Elamipretide | Placebo |
|---|---|---|
| Injection site erythema | 100% | 25% |
| Injection site pain | 75% | 42% |
| Injection site induration | 67% | 17% |
| Injection site pruritus | 67% | 17% |
| Injection site bruising | 25% | 0% |
| Injection site urticaria | 25% | NR |
All patients in the pivotal Barth trial experienced at least one local administration reaction. Reactions generally mild to moderate. No patient discontinued due to injection site reactions.
Serious adverse events
- Deaths: none reported in the FORZINITY clinical development program for Barth syndrome
- Discontinuation due to AEs: low; 2/12 in OLE discontinued for non-AE reasons
Key safety concerns for off-label use
- 100% injection site reaction rate — even in the approved indication
- No long-term safety data beyond 192 weeks in only 8 Barth syndrome patients
- No safety data in healthy adults — all dosing data from patients with severe mitochondrial disease
- Unknown immunogenicity — anti-drug antibody data not publicly disclosed
- Financial cost — orphan drug pricing; no proven benefit for off-label use
Contraindications
Serious hypersensitivity to elamipretide or any excipient in FORZINITY.
Drug interactions
- No formal DDI studies beyond aspirin
- No significant QTc prolongation at 3× therapeutic Cmax
- Renal dose reduction required: CrCl <30 mL/min → reduce to 20 mg once daily
Wearable / Vitals Relevance
Zero established wearable signal. No studies have used consumer wearables to measure any biometric during SS-31 treatment.
Theoretical pathways (none confirmed):
- HRV: improved cardiac mitochondrial function → improved autonomic balance — no human data
- RHR: improved cardiac efficiency → lower resting heart rate — no data
- Exercise capacity / VO2 max: improved oxidative phosphorylation → higher peak aerobic power — no wearable data
- Sleep quality: reduced cellular oxidative stress → improved sleep — entirely theoretical
- Fatigue: most directly relevant symptom — trials that attempted to measure it (6MWT) failed in general PMM population
SS-31 has zero wearable relevance based on current evidence. This is an area that could be studied — continuous HRV and activity monitoring during SS-31 treatment in Barth syndrome or PMM patients would be scientifically valuable — but no such data exists.
Best Stack Context
No case for SS-31 in Ben’s stack (Retatrutide + GHK-Cu + BPC-157/TB-500).
- Ben is training daily, metabolically healthy on Retatrutide, and has no diagnosed mitochondrial disease
- The claim that SS-31 supports “mitochondrial health” in healthy adults is marketing language, not clinically validated
- No data on combining SS-31 with GHK-Cu, BPC-157, TB-500, or Retatrutide
- The only study in healthy older adults showed zero functional benefit
Bottom line: SS-31 is scientifically interesting with genuine mechanistic promise for conditions where cardiolipin itself is pathologically abnormal (Barth syndrome). For everyone else — including healthy, training adults — the evidence says no.
Aspirational Links
- ~Cardiolipin — planned future mechanism note for the IMM phospholipid target
- ~Mitochondrial Ferroptosis — planned future mechanism note for the mitoGSH/mitoGPX4 pathway
Related Notes
- Retatrutide — no interaction; different mechanism class
- GHK-Cu — tissue repair; different mechanism class; no combined-use data
- BPC-157 — GI repair and tendinous healing; different mechanism class; no combined-use data
- TB-500 — anti-inflammatory and tissue repair; different mechanism class; no combined-use data
Key PMIDs
| PMID | Study | Key Finding |
|---|---|---|
| 33077895 | Thompson et al., 2020 | Barth syndrome pivotal: failed primary endpoints in RCT portion; OLE data used for approval |
| 38602181 | Thompson et al., Genet Med 2024 | TAZPOWER OLE 168-week: +96.1 m 6MWT, improved cardiac volumes — open-label only |
| 37268435 | Karaa et al., Neurology 2023 | MMPOWER-3 Phase 3 PMM: failed co-primary endpoints — NEGATIVE |
| 39574155 | et al., Orphanet J Rare Dis 2024 | MMPOWER-3 post-hoc: benefit limited to POLG/TWNK nDNA variant subgroup |
| 32068002 | et al., 2020 | PROGRESS-HF Phase 2 HFrEF: no improvement in LVESV — NEGATIVE |
| 34264994 | et al., 2022 | Healthy older adults: transient ATPmax improvement in one muscle; no functional benefit — NEGATIVE |
| 23813215 | Birk et al., JASN 2013 | SS-31 accelerates ATP recovery after ischemia-reperfusion — cell/animal |
| 36400945 | Russo et al., Sci Rep 2022 | SS-31 improves mitochondrial capacity in TAFAZZIN knockdown mice |
| 39364755 | Xiong et al., IJMM 2024 | SS-31 activates mitoGSH/mitoGPX4 pathway, alleviates mitochondrial ferroptosis |
Canonical source: skills/knowledge-base/compounds/ss31-elamipretide.md | Created: 2026-04-18